Clinical Trial Update: Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Hycamtin (Topotecan)
• Tykerb (lapatinib)

Snippet

Sponsor: Centre Francois Baclesse | Conditions: Cancer, Ovarian | Phase 2 | Status: TERMINATED